Clinical Trial

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-01
Trial Details
NCT Number NCT07512427
Lead Sponsor OPKO Health, Inc.
Conditions MASH
Enrollment 30 participants
Start Date 2026-07-24
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31